INMB
Price
$2.53
Change
+$0.17 (+7.20%)
Updated
Jul 3 closing price
Capitalization
68.92M
24 days until earnings call
OVID
Price
$0.34
Change
+$0.01 (+3.03%)
Updated
Jul 3 closing price
Capitalization
24.06M
42 days until earnings call
Interact to see
Advertisement

INMB vs OVID

Header iconINMB vs OVID Comparison
Open Charts INMB vs OVIDBanner chart's image
INmune Bio
Price$2.53
Change+$0.17 (+7.20%)
Volume$4.7M
Capitalization68.92M
Ovid Therapeutics
Price$0.34
Change+$0.01 (+3.03%)
Volume$283.19K
Capitalization24.06M
INMB vs OVID Comparison Chart in %
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. OVID commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and OVID is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (INMB: $2.53 vs. OVID: $0.34)
Brand notoriety: INMB and OVID are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 156% vs. OVID: 28%
Market capitalization -- INMB: $68.92M vs. OVID: $24.06M
INMB [@Biotechnology] is valued at $68.92M. OVID’s [@Biotechnology] market capitalization is $24.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileOVID’s FA Score has 1 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • OVID’s FA Score: 1 green, 4 red.
According to our system of comparison, OVID is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 5 TA indicator(s) are bullish while OVID’s TA Score has 5 bullish TA indicator(s).

  • INMB’s TA Score: 5 bullish, 5 bearish.
  • OVID’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OVID is a better buy in the short-term than INMB.

Price Growth

INMB (@Biotechnology) experienced а -59.71% price change this week, while OVID (@Biotechnology) price change was -1.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

INMB is expected to report earnings on Jul 30, 2025.

OVID is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INMB($68.9M) has a higher market cap than OVID($24.1M). INMB YTD gains are higher at: -45.824 vs. OVID (-63.757). INMB has higher annual earnings (EBITDA): -41.52M vs. OVID (-56.4M). OVID has more cash in the bank: 43M vs. INMB (19.3M). INMB has less debt than OVID: INMB (347K) vs OVID (14.4M). OVID has higher revenues than INMB: OVID (548K) vs INMB (50K).
INMBOVIDINMB / OVID
Capitalization68.9M24.1M286%
EBITDA-41.52M-56.4M74%
Gain YTD-45.824-63.75772%
P/E RatioN/AN/A-
Revenue50K548K9%
Total Cash19.3M43M45%
Total Debt347K14.4M2%
FUNDAMENTALS RATINGS
INMB vs OVID: Fundamental Ratings
INMB
OVID
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
9763
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OVID's Valuation (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for INMB (82) in the Biotechnology industry. This means that OVID’s stock grew somewhat faster than INMB’s over the last 12 months.

OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as INMB (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to INMB’s over the last 12 months.

OVID's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as INMB (99) in the Biotechnology industry. This means that OVID’s stock grew similarly to INMB’s over the last 12 months.

OVID's Price Growth Rating (63) in the Pharmaceuticals Major industry is somewhat better than the same rating for INMB (97) in the Biotechnology industry. This means that OVID’s stock grew somewhat faster than INMB’s over the last 12 months.

OVID's P/E Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as INMB (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMBOVID
RSI
ODDS (%)
Bullish Trend 4 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
79%
MACD
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
73%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 24 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CZASF0.01N/A
N/A
China Zhengtong Auto Services Holdings Ltd.
NLLSY7.20N/A
N/A
Nel ASA
SNANF0.36N/A
N/A
Sona Nanotech Inc
BDLNF0.16N/A
N/A
Badlands Resources Inc.
COVTY35.53-0.33
-0.91%
Covestro AG

INMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with UBX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then UBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
+7.20%
UBX - INMB
55%
Loosely correlated
-1.71%
ABCL - INMB
46%
Loosely correlated
+1.33%
GBIO - INMB
36%
Loosely correlated
+1.51%
PROK - INMB
36%
Loosely correlated
+10.11%
OVID - INMB
35%
Loosely correlated
+2.39%
More

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
+2.39%
JBIO - OVID
79%
Closely correlated
+3.15%
BEAM - OVID
47%
Loosely correlated
+0.65%
TRDA - OVID
47%
Loosely correlated
N/A
DNLI - OVID
46%
Loosely correlated
-1.41%
CRNX - OVID
46%
Loosely correlated
+1.22%
More